Neutralization Profile after Recovery from SARS-CoV-2 Omicron Infection, N Engl J Med 2022; 386:1764-1766 「新型コロナウイルス・オミクロン株感染から回復後の中和に関する一側面」（『ニューイングランド・ジャーナル・オヴ・メディスン』 2022年 386巻 1764 - 1766ページ）
図1
| Figure 1. Neutralization Capacity of Serum Samples Obtained from Patients Who Recovered from Infection with the Omicron BA.1 Variant. | |||
| （新型コロナウイルス・オミクロン株感染から回復後の中和に関する一側面） | |||
| Serum samples were obtained from 59 persons who had recovered from infection with the B.1.1.529 (omicron) BA.1 variant: 15 vaccinated persons without previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (Panel A); 18 unvaccinated persons without previous SARS-CoV-2 infection (Panel B); 11 vaccinated persons with previous infection with the D614G (wild-type), B.1.1.7 (alpha), or B.1.617.2 (delta) variant (Panel C); and 15 unvaccinated persons with previous infection with the wild-type, alpha, or delta variant (Panel D). Serum samples were obtained from each person 5 to 42 days after the first positive polymerase-chain-reaction assay during infection with the omicron BA.1 variant. Samples were analyzed for 50% neutralization titers (IC50) with the use of replication-competent wild-type, alpha, beta, P.1 (gamma), delta, or omicron BA.1 SARS-CoV-2 isolates. Individual values (circles) and mean titers (bars) are shown. Samples from the same person are connected by lines. Titers below 1:16 (dotted lines) are regarded as negative. In Panels B and D, the numbers above the bars indicate the proportions of samples that were positive for neutralizing antibodies against the respective variant. In Panels A and C, all the samples were positive for neutralizing antibodies against all the variants. | |||
アカデミア神戸 大人のための教養講座 インデックスに戻る
アカデミア神戸 トップページに移動する
Ἀναστασία ἡ Οὐτοπία τῶν αἰλούρων ANASTASIA KOBENSIS, ANTIQUARUM RERUM LOCUS NON INVENIENDUS